General technical commentary only — not financial advice. Full disclaimer below.
SwingRoo ← All charts

4DX · ASX · Published October 11, 2026 · Based on Fri, Oct 9 close IN FOCUS

4dmedical

$4.05 −46.4% from 52-week high ($7.55) · +189.3% from 52-week low ($1.40)
Support
$4.01
Resistance
$4.31
Invalidation
$3.59
ATR(14)
5.7%

This analysis is based on closing-price data as of October 9, 2026. Whether you're researching 4dmedical (4DX) on the ASX or learning how to read stock charts, here are objective support, resistance and technical invalidation levels built from the RSI, MACD and ATR indicators.

4dmedical closed at $4.05, 46.4% below its $7.55 52-week high and 189.3% above the $1.40 low. On the two-year chart the stock advanced from a sub-$1 base in mid-2025 to a peak in April 2026, fell back sharply in May, and has since moved sideways in a broad range of roughly $3 to $4.70 — so the larger picture is a range, not an advance. Inside that range, a September 8 to September 18 swing from $3.35 to $4.31 put the SMA5 > SMA20 > SMA60 ordering in place on September 30, and the past week has been a pullback from the $4.36 close of October 1 back to the 20-day line. Friday's close re-took both SMA20 and SMA60 on quiet volume, while a fresh MACD dead cross, a bearish RSI divergence and an ADX of 16.0 temper the read; on the other side, OBV shows a bullish divergence at the pullback low.

Snapshot as of October 9, 2026

ItemValueReading
Close$4.05−46.4% from 52w high · +189.3% from 52w low
52-week range$1.40 – $7.55Close in the middle of the range, far below the high
SMA 5 / 20 / 60$4.026 / $4.013 / $3.794Close > SMA5 > SMA20 > SMA60, ordering in place since Sep 30. Close is only 0.9% above SMA20 and 6.7% above SMA60
Bollinger (20)$4.491 / $4.013 / $3.535Band width 23.8%; the close sits just above the mid line, 9.8% below the upper band
aVWAP (2y anchor Aug 1, 2025)$3.354Price 20.8% above the long-horizon anchored average
aVWAP (90d anchor Jul 17, 2026)$3.830Price 5.7% above the average anchored to the July low
RSI(14)53.0Neutral; bearish divergence flagged — $4.31 at RSI 63.92 on Sep 18 versus a higher $4.36 at RSI 62.96 on Oct 1
Mansfield RS (vs the S&P/ASX 200)+11.9%Outperforming, slope rising; −9.69 points on the week (slowing), +14.77 points on the month
MACD (12,26,9)0.0879 / 0.1038 / −0.0159Dead cross on Oct 8 above the zero line; the Sep 15 golden cross has been reversed
ADX(14)16.0Below 20 — ranging, no directional regime (15.7 on the two-year frame)
ATR(14)$0.230 (5.7%)A wide daily range; 2×ATR spans 11.4% of the share price
OBV (2y / 90d)early accumulation / accumulationAbove MA20 on both frames — flat on two years, rising on 90 days. Bullish OBV divergence on the 90-day frame
Volume vs 20d avg0.62×2,471,014 shares against a 3,963,793 average; roughly 0.84× after adjusting for a quiet market
1×ATR / 2×ATR technical invalidation$3.82 / $3.59Volatility-based structural reference levels below the close

① Price & Moving Averages

4DX price, moving averages, Bollinger Bands and anchored VWAP — 90 days

The two-year chart sets the frame: after the April 2026 peak and the May drop, price has spent five months inside a broad range of roughly $3 to $4.70, and the SMA60 at $3.794 has flattened rather than rising. Within that, the 90-day view shows a September 8 low at $3.35, a jump to $4.31 on September 18, and a higher close of $4.36 on October 1. That swing produced the SMA20 > SMA60 crossover and the full SMA5 > SMA20 > SMA60 ordering on September 30.

The pullback since October 1 took price back below the 23.6% retracement of the Sep 8–Sep 18 swing ($4.08) and to $3.95 on October 8, just above the 38.2% level ($3.94). Friday's $4.05 close re-established price above both SMA20 and SMA60. The 50% retracement ($3.83) coincides almost exactly with the 90-day anchored VWAP ($3.830), and an unfilled gap from September 18 sits at $3.80–$3.89 — a layered support zone under the 20-day line. On the two-year Fibonacci (Apr 10 high $6.80 to Apr 30 low $4.01), the 23.6% retracement at $4.67 is the first overhead reference beyond the recent highs.

One piece of context on the September 18 bar: it fell on the S&P/ASX September quarterly rebalance trading day, when market-wide volume was elevated (universe median about 2.28× normal). 4DX was already an ASX 200 member before that date, and on a market-adjusted basis the bar's volume was about 1.46× rather than the raw 3.25×. The twenty-day-high break and the swing high that anchor this pullback both date from that bar.

② Volume

4DX volume with 20-day average — 90 days

Friday's 2,471,014 shares were 0.62× the 20-day average of 3,963,793. The whole ASX was quiet in the week (universe median volume ratios of 0.45× to 0.81×), so adjusted for that the bar was about 0.84× typical participation — at or below normal, not heavy. The 20-day average itself has drifted lower through September and October.

The higher-participation bars of the swing came on September 30 (+4.17%, about 1.34× market-adjusted) and October 1 (+2.59%, about 2.19×). The October 5 drop of 6.22% was on 0.74× raw volume, about 1.63× market-adjusted — noticeable, but well short of a heavy-volume break. No public catalyst was identified for these bars. The pullback days since then have been on lighter volume, which is consistent with a pause rather than distribution, but the recovery bar on Friday has not yet drawn volume either.

③ MACD

4DX MACD 12-26-9 — 90 days

MACD crossed above its signal line on September 15 from below zero, rose above zero, and peaked in early October. On October 8 it crossed back below the signal line: the current values are 0.0879 for MACD, 0.1038 for the signal and −0.0159 for the histogram. Both lines remain above zero, so this is a loss of momentum within a positive reading rather than a shift to negative territory. A pullback that resolves upward would normally show the histogram shrinking back toward zero first; a widening negative histogram would point to a deeper retracement.

④ RSI

4DX RSI 14 with overbought and oversold zones — 90 days

RSI(14) is 53.0, back near the midline after peaking in the low 60s. A bearish divergence is flagged: price closed at $4.31 with RSI 63.92 on September 18, then at a higher $4.36 with RSI 62.96 on October 1. The gap between the two RSI readings is small, and the pullback since then has already worked off some of the momentum it described. A divergence is a possibility of a top, not a confirmation; it would gain weight if price closed below the 20-day line and the September lows came into play, and it would lose relevance on a new closing high above $4.36 with RSI above 63.92.

⑤ Mansfield Relative Strength

4DX Mansfield relative strength versus the S&P/ASX 200 — 90 days

Mansfield RS versus the S&P/ASX 200 reads +11.9%, above zero with a rising slope tag. Against the prior week (+21.55) it has given back 9.69 points — positive but slowing — while against a month ago (−2.92) it is 14.77 points higher, having crossed back above zero during the September swing. On the two-year chart RS has compressed steadily from the very high readings of late 2025 to near zero over the summer, so the current reading is modest outperformance rather than leadership.

⑥ ATR & ADX

4DX ATR 14 and ADX 14 — 90 days

ATR(14) is $0.230, or 5.7% of price — a wide daily range for a stock at this level, though ATR has been trending lower since the summer. That puts the 1×ATR reference at $3.82 and the 2×ATR technical invalidation level at $3.59, 11.4% under the close. ADX is 16.0 (15.7 on the two-year frame), below the 20 threshold: the market is not in a directional regime, and the moving-average ordering is forming inside a range rather than confirming a trend.

⑦ OBV

4DX on-balance volume with 20-day average — 90 days

On the 90-day frame OBV is tagged accumulation — above its MA20 with a rising slope — and a bullish OBV divergence is flagged: price made a lower close of $3.95 on October 8 against $3.99 on September 28, while OBV made a higher reading (−2,585,170 versus −4,275,394). On the two-year frame OBV is tagged early accumulation, 0.41% above its MA20 with a flat slope. The two oscillators therefore point in opposite directions — RSI bearish on the highs, OBV bullish on the pullback low — and neither is confirmed by price yet. The 90-day OBV-to-MA20 gap of 88.94% reflects an MA20 close to zero and is not a measure of strength.

Bull Case vs Bear Case

Bull Case

  • Close > SMA5 > SMA20 > SMA60, ordering in place since Sep 30; Friday's close re-took SMA20 and SMA60
  • The pullback held above the 38.2% retracement ($3.94) of the Sep 8–Sep 18 swing
  • Bullish OBV divergence: $3.95 on Oct 8 below $3.99 on Sep 28, with OBV higher (−2,585,170 vs −4,275,394)
  • Layered support at $3.80–$3.89: Sep 18 unfilled gap, 50% retracement and the $3.830 90-day aVWAP
  • Mansfield RS +11.9% versus the S&P/ASX 200, +14.77 points on the month
  • Price above both anchored VWAPs — $3.354 (Aug 1, 2025) and $3.830 (Jul 17, 2026)

Bear Case

  • MACD dead cross on Oct 8, histogram −0.0159
  • Bearish RSI divergence: $4.31 at RSI 63.92 on Sep 18 against a higher $4.36 at RSI 62.96 on Oct 1
  • ADX 16.0 — no directional regime; the larger chart has ranged between roughly $3 and $4.70 since May
  • Close only 0.9% above SMA20, on volume about 0.84× market-typical
  • Relative strength slowing: −9.69 points on the week
  • ATR 5.7% of price; the 2×ATR invalidation line is 11.4% below and the 52-week high is 46.4% above

Scenarios

ScenarioProbabilityPathTrigger / Invalidation
Pullback resolves upward 35% Price holds above the $4.01 SMA20, clears the $4.08 23.6% retracement, and retests the $4.31–$4.36 swing highs; the OBV divergence is confirmed and the MACD histogram turns back toward zero. Trigger: a daily close above $4.36 with volume above its average. Invalidation: a daily close below $3.94.
Range continues 40% ADX below 20 is taken at face value: price oscillates between the $3.80–$3.89 support layer and the $4.31–$4.36 highs while the RSI and OBV divergences stay unresolved. Trigger: daily closes between $3.83 and $4.36 with ADX below 20. Invalidation: a close outside either edge.
Pullback deepens 25% The MACD dead cross and the RSI divergence receive price confirmation: a close below the $3.83 aVWAP and 50% retracement, filling the Sep 18 gap, then a test of the $3.79 SMA60 and the $3.59 2×ATR level. Trigger: a daily close below $3.80. Invalidation: recovery to a daily close above $4.08.

Key Levels & Volatility References

LevelRoleDistanceBasis
$4.49Resistance+10.9%Upper Bollinger Band (20) at 23.8% band width
$4.31Resistance+6.4%90-day Fibonacci 0% anchor (Sep 18 high); the Oct 1 close of $4.36 sits just above
$4.05Current—Oct 9, 2026 close; the 23.6% retracement ($4.08) sits just above
$4.01Support−0.9%SMA20 / Bollinger mid line ($4.013), two-year Fibonacci 0% anchor ($4.01); SMA5 ($4.026) alongside
$3.83Support−5.4%90-day aVWAP ($3.830, anchor Jul 17) and 50% retracement; Sep 18 unfilled gap $3.80–$3.89 and 1×ATR ($3.82) in the same zone
$3.79Support−6.3%SMA60 ($3.794)
$3.59Invalidation−11.4%2×ATR technical invalidation level

What to Watch

Conclusion

4dmedical closed at $4.05 after a pullback from the $4.36 October 1 high, re-taking the 20-day line inside an SMA5 > SMA20 > SMA60 ordering that dates from September 30, with layered support below at $3.80–$3.89 and a bullish OBV divergence at the October 8 low. Against that, MACD made a dead cross on October 8, RSI shows a bearish divergence on the highs, ADX of 16.0 registers no trend, Friday's volume was below market-typical, and the two-year chart remains a broad range far below the $7.55 52-week high — a pullback structure that has paused, not one that has resumed. The objective line beneath it is the 2×ATR technical invalidation level at $3.59, 11.4% below the close; a daily close under it would undo the September swing structure described here, while the $4.01 SMA20 and the $3.83 aVWAP are the nearer shelves.

Past Analyses of This Stock same ticker · newest first

Other signals from this issue same publication date · 3 stocks

SwingRoo publishes technical chart commentary for general information and entertainment purposes only. Nothing on this site is financial product advice, and SwingRoo does not hold an Australian Financial Services Licence (AFSL). We make no recommendation to buy, sell or hold any security. Levels shown are technical observations, not price targets. All trading involves risk of loss. Before making investment decisions, consider seeking advice from a licensed financial adviser. We receive no payment from any company mentioned.
SwingRoo · swingroo.com · S&P/ASX 300 screened weekly

← All charts